HealthEquity (HQY)
(Delayed Data from NSDQ)
$98.82 USD
+1.62 (1.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$98.82 USD
+1.62 (1.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Zacks News
HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio
by Zacks Equity Research
OPKO Health's (OPK) potential in RAYALDEE raises optimism about the stock.
NextGen (NXGN) to Offer AI-Based Patient Engagement Solutions
by Zacks Equity Research
NextGen (NXGN), in alliance with Luma Health, is set to offer AI-enhanced solutions for patient communications to ambulatory organizations nationwide.
Masimo's (MASI) Stork Baby Monitor Now Available Across U.S.
by Zacks Equity Research
The latest U.S. availability of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Fresenius Medical's (FMS) New HHD Device to Increase Portability
by Zacks Equity Research
Fresenius Medical (FMS) gets FDA clearance for Versi HD with GuideMe Software, a portable, home hemodialysis device with an easy-to-use graphical interface providing easier training experiences.
NextGen (NXGN) Behavioral Health Suite to Address Mental Health
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to ease state reporting and enable the secure sharing of patient information across providers.
Here's Why You Should Invest in HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Masimo's (MASI) PVi Favored by Study for GDFT in Elderly Patients
by Zacks Equity Research
Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fluid administered in elderly patients during GI surgery.
Premier, Inc. (PINC) Tops Q4 Earnings Estimates
by Zacks Equity Research
Premier, Inc. (PINC) delivered earnings and revenue surprises of 1.49% and 5.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
THRN vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
THRN vs. HQY: Which Stock Is the Better Value Option?
Reasons to Retain West Pharmaceutical (WST) Stock for Now
by Zacks Equity Research
West Pharmaceutical's (WST) strength in its proprietary products segment raises optimism about the stock.
Nevro's (NVRO) New Data Supports SCS Therapy for PDN Treatment
by Zacks Equity Research
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS implant for durable pain relief and significant improvements in patient condition post-implantation.
McKesson (MCK) & Genpact Extend Tie Up to Improve Workflow
by Zacks Equity Research
McKesson's (MCK) latest partnership extension is likely to transform its finance operations for enhanced service and competitive growth.
Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how HealthEquity (HQY) and InMode (INMD) have performed compared to their sector so far this year.
AngioDynamics' (ANGO) New FDA Recognition to Boost Treatment
by Zacks Equity Research
The FDA's grant of the Breakthrough Device designation for AngioDynamics' (ANGO) AngioVac is likely to remove thrombus and embolic material and minimize blood loss via blood recirculation.
Patterson Companies (PDCO) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) broad product line.
3 Reasons to Retain DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
Biote Corp. (BTMD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
biote Corp. (BTMD) delivered earnings and revenue surprises of 340% and 5.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Apollo Medical Holdings, Inc. (AMEH) Meets Q2 Earnings Estimates
by Zacks Equity Research
Apollo Medical Holdings, Inc. (AMEH) delivered earnings and revenue surprises of 0% and 2.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Receives FDA Nod to Address Critical Infusion Needs
by Zacks Equity Research
The latest regulatory clearance for BD's (BDX) Alaris Infusion System is expected to improve healthcare system efficiency via better care coordination and utilization of actionable information.
Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Avantor's (AVTR) New Expansion Plans to Boost Workflow
by Zacks Equity Research
Avantor's (AVTR) latest expansion plans are likely to aid customers in creating customized workflow solutions.
New Strong Buy Stocks for July 20th
by Zacks Equity Research
HQY, SKFRY, AZEK, CIR and ATR have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 2023.